Avalyn Pharma Inc.
AVLNNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2026-12AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
- Phase 2Recruitingreadout ~2027-06A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
- Phase 2Recruitingreadout ~2031-12-31An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Sr One Capital Management, LlcActivist (13D)May 8, 2026
- Suvretta Capital Management, LlcActivist (13D)May 8, 2026
- Perceptive Advisors LlcPassive (13G)May 7, 2026
- Fmr LlcPassive (13G)May 5, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Novo Holdings A/S10% owner | May 1, 2026 | Conversion | 3.3M | — |
| Fmr Llc10% owner | May 1, 2026 | Conversion | 727,585 | — |
| Carroll JillDirector | May 1, 2026 | Conversion | 1.4M | — |
| Sr One Capital Management, Llc10% owner | May 1, 2026 | Conversion | 1.4M | — |
| Wellington Biomedical Innovation Master Investors (Cayman) Ii L.P.10% owner | May 1, 2026 | Conversion | 1.3M | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 562,374 | 1.4 | +100.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recentEvents the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13DMay 8, 2026
- SCHEDULE 13DMay 8, 2026
- SCHEDULE 13GMay 7, 2026
- 4May 5, 2026
- SCHEDULE 13GMay 5, 2026
- 4May 5, 2026
- 4May 4, 2026
- 4May 1, 2026
- 4May 1, 2026
- 4May 1, 2026
- 4May 1, 2026
- 4May 1, 2026
- 4May 1, 2026
- 4May 1, 2026
- 4May 1, 2026